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Abstract: A new series of 3-chloro-4-(substituted phenyl)-1-{[2-(2-thiazolylami-
no)ethyl]amino}-2-azetidinone, compounds 4a–m, has been synthesized from 
2-aminothiazole as the starting material. The structures of all the synthesized 
compounds were confirmed by chemical and spectral analyses, such as FTIR, 
1H-NMR and 13C-NMR spectroscopy. All the final synthesized compounds 
4a–m  were screened for their antibacterial and antifungal activities against 
some selected bacteria and fungi and for their antitubercular activity against 
Mycobacterium tuberculosis, and  their minimum inhibitory concentration 
(MIC) values were determined. The anti-inflammatory activities of the title 
compounds were screened using albino rats (either sex) and gave acceptable re-
sults. 
Keywords: synthesis; 2-aminothiazole; azetidinone; antimicrobial; antitubercu-
lar; anti-inflammatory. 
INTRODUCTION 
The azetidinone unit is a crucial structural feature of significant classes of 
antibiotics and its chemistry is very important to their biological activities, for 
instance, the penicillin and cephalosporin antibiotics possess cis-β-lactam units, 
whereas the thienamycins and trinems have trans-β-lactam moieties. The 
effective synthesis of β-lactam became a desirable goal based on the discovery of 
penicillin and cephalosporin. Although most penicillin and cephalosporin related 
compounds are obtained by biosynthesis, chemical modification of intermediates 
for bioassay of the antibacterial activity of the resulting compounds has become 
of utmost importance because of the growing resistance of bacteria against pe-
nicillin- and cephalosporin-like compounds and the need for medicines with 
more specific antibacterial activity.1,2 The azetidinone derivatives have also been 
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recognized as tumor necrosis factor-alpha (TNF-alpha) converting enzyme (TACE) 
inhibitors3 and agents with new biological activities, such as anticancer,4 anti-
coccidial,5 cardiovascular,6 antiviral,7 mutagenic,8 anticonvulsant and anti-in-
flammatory.9,10 Condensed heterocyclic systems are of considerable interest not 
only because of their potential biological activity, but also because of their ver-
satility as synthons in organic transformations.  
The thiazole moiety is also an important component of the pharmacophores 
of a large number of molecules of medicinal significance and the evaluation of 
their biological activity, such as antiprotozoal,11 antibacterial,12 antifungal,13,14 
antitubercular15 and anthelmintic,16 with emphasis on their potential medicinal 
applications, is desirable. Moreover, thiazole derivatives have attracted a great 
deal of interest due to their wide applications in the field of pharmaceuticals.  
In the present study, a series of N-[2-(2-aminothiazolyl)ethyl]-4-(substituted 
phenyl)-3-chloro-2-oxo-1-iminoazetidines, compounds 4a–m, was synthesized as 
shown in Scheme 1. The structure of all the synthesized compounds was elu-
cidated by FTIR, 1H-NMR,  13C-NMR, and chemical methods. All the final 
compounds 4a–m were screened for their antibacterial, antifungal, antitubercular 
and anti-inflammatory activities. 
NH2NH2.H2O
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S N
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Compound Ar  Compound  Ar 
3a and 4a  C6H5  3h and 4h  4-NO2C6H4 
3b and 4b  4-ClC6H4  3i and 4i  3-NO2C6H4 
3c and 4c  3-ClC6H4  3j and 4j  2-NO2C6H4 
3d and 4d  2-ClC6H4  3k and 4k  4-CH3OC6H4 
3e and 4e  4-BrC6H4  3l and 4l  4-CH3C6H4 
3f and 4f  3-BrC6H4  3m and 4m  4-HOC6H4 
3g and 4g  2-BrC6H4 –  – 
Scheme 1. Synthesis of compounds 1–4. 
EXPERIMENTAL 
Melting points were taken in open capillaries and are uncorrected. The progress of the re-
actions was monitored by silica gel-G coated TLC plates using MeOH:CHCl3 (2:8) system. 
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The spot was visualized by exposing the dry plate to iodine vapors. The IR spectra were re-
corded in KBr discs on a Shimadzu 8201 PC FTIR spectrophotometer (νmax in cm-1) and the 
1H-NMR and 13C-NMR spectra were measured on a Bruker DRX-300 spectrometer in CDCl3 at 
300 and 75 MHz, respectively, using TMS as an internal standard. All chemical shifts are 
reported on δ scales. Elemental analyses were realized on a Carlo Erba-1108 analyzer. The 
analytical data of all the compounds were satisfactory. For column chromatographic 
purification of the products, Merck silica gel 60 (230–400 mesh) was used. The reagent grade 
chemicals were purchased from commercial sources and further purified before use. 
Procedure for the synthesis of 2-[(2-chloroethyl)amino]thiazole, compound 1 
2-Aminothiazole and 1-bromo-2-chloroethane (1:1 mole) were dissolved in methanol. 
The reaction mixture was continuously stirred on a magnetic stirrer at 30–35 °C for about 8 h. 
The product was filtered and purified by column chromatography. The purified product was 
dried in the oven at 45–50 °C for 8 h and recrystallized from ethanol to yield compound 1. 
Procedure for the synthesis of N-(2-hydrazinylethyl)-thiazolamine, compound 2 
Compound 1 and hydrazine hydrate (1:1 mole) were dissolved in methanol at room tem-
perature. The reaction mixture was continuously stirred on a magnetic stirrer at 30–35 °C for 
about 5 h. The product was filtered off and purified by column chromatography. The purified 
product was dried in an oven at 45–50 °C for 9 h and recrystallized from ethanol to yield 
compound 2. 
General procedure for the synthesis of substituted benzaldehyde, 2-[2-(thiazolylamino)ethyl]-
hydrazone, compounds 3a–m 
Compound 2 and an appropriate substituted benzaldehyde (1:1 mole) were dissolved in 
methanol and allowed to reaction. The reaction mixture was first continuously stirred on a 
magnetic stirrer at 30–35 °C for about 3–5 h and then kept on a steam bath at 75–90 °C for 
about 3–4 h. The products were filtered and cooled to room temperature. The filtered products 
were purified by column chromatography. The purified products were dried in an oven at 55– 
–60 °C for 6–10 h and recrystallized from ethanol to yield compounds 3a–m. 
General procedure for the synthesis of 3-chloro-4-(substituted phenyl)-1-{[2-(2-thiazolylami-
no)ethyl]amino}-2-azetidinone, compounds 4a–m 
An appropriate compound 3a–m and chloroacetyl chloride in the presence of Et3N (1:1:1 
mole ratio) were dissolved in methanol (50 ml) and allowed to react. The reaction mixture was 
first continuously stirred on a magnetic stirrer at 30–35 °C for about 3–4 h and then kept on a 
steam bath at 70–85 °C for about 3–5 h. The products were filtered and cooled to room tempe-
rature. The filtered products were purified by column chromatography. The purified products 
were dried in an oven at 60–65 °C for 4–8 h and recrystallized from ethanol to yield com-
pounds 4a–m, respectively. 
Biological importance 
The antibacterial, antifungal and antitubercular activities of compounds 4a–m were as-
sayed in vitro against selected bacteria: Bacillus subtilis, Escherichia coli, Staphylococcus au-
reus and Klebsiella pneumoniae, and fungi: Aspergillus niger, A. flavus, Candida albicans and 
Fusarium oxysporum, and Mycobacterium tuberculosis (H37Rv) strain. The minimal inhibi-
tory concentration (MIC) values of compounds 4a–m were determined using the filter paper 
disc diffusion method (antibacterial and antifungal activity) and the Lowenstein–Jensen (LJ) 
medium (conventional) method (antitubercular activity) at 100 μg mL-1 and lower concentra-
tions. Streptomycin and griseofulvin, used as the standard for the antibacterial and antifungal 
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activity, respectively, showed MIC values in the range 1.25–3.25 μg mL-1 for all the bacterial 
strain and 6.25–12.5 μg mL-1 for all fungal strain. For the antitubercular activity, isoniazid and 
rifampicin were taken as standards (MIC range 1.25–2.50 μg mL-1). All standards were also 
screened under similar condition for comparison. 
Anti-inflammatory activity 
The carageenan-induced rat paw edema method was employed for evaluating the anti-
inflammatory activity of the compounds at a dose 50 mg kg–1 bw in albino rats (weighing 80–
110 g, each group contained 5 animal) using phenylbutazone as the standard drug for compa-
rison at a dose 30 mg kg-1 body weight. The rate paw edema was produced by the method of 
Winter et al.17 The percentage inhibition of inflammation was calculated by applying the 
Newbould formula.18 
RESULTS AND DISCUSSION 
3-Chloro-4-(substituted phenyl)-1-{[2-(2-thiazolylamino)ethyl]amino}-2- 
-azetidinone, compounds 4a–m, were synthesized in four different steps. 
2-Aminothiazole on reaction with Cl(CH2)2Br at room temperature afforded 
2-[(2-chloroethyl)amino]thiazole, compound 1. The IR spectrum of compound 1 
displayed absorptions at 1336 and 740 for (C–N) and (C–Cl), respectively, this 
clearly indicated the synthesis of compound 1. Compound 1 on reaction with 
hydrazine hydrate at room temperature yielded N-(2-hydrazinylethyl)-2- 
-thiazolamine, compound 2. The IR spectrum of compound 2 showed absorptions 
for NH and NH2 at 3378 and 3429 cm–1, respectively, while the absorption for 
(C–Cl) in the IR spectrum of compound 1 had disappeared. The 1H-NMR spec-
trum of 2 displayed signals at δ 7.63 and 5.56 ppm for NH and NH2, respectively. 
Compound  2 on further reaction with several selected substituted aromatic 
aldehydes produced substituted benzaldehyde, 2-[2-(thiazolylamino)–ethyl]–
hydrazone, compounds 3a–m. The characteristic absorption for a Schiff base 
(N=CH) appeared in the range 1542–1579 cm–1 in the IR spectra of compounds 
3a–m and in the 1H- and 13C-NMR spectra signals appeared at δ 7.82–8.12 and δ 
151.6–157.4 ppm, respectively. In the 1H-NMR, the broad signal of NH2 present 
in the spectrum of compound 2 had disappeared. Compounds 3a–m on treatment 
with ClCH2COCl in the presence of Et3N furnished the final products, 
compounds 4a–m. In the  IR spectra of compounds 4a–m, the carbonyl group of 
the  β-lactam ring showed a characteristic absorption in the range 1726– 
–1752 cm–1 and the 1H-NMR spectra of compounds 4a–m showed two doublets 
for (N–CH) and (CH–Cl) in the range δ 4.72–4.98 and 4.13–4.28 ppm, res-
pectively. In the 13C-NMR spectra of compounds 4a–m, three characteristic 
signals appeared for (N–CH), (CH–Cl) and (CO cyclic) in the δ ranges 60.8– 
–65.7, 49.7–54.8 and 169.8–176.4 ppm, respectively. The IR absorption and 
1H- and 13C-NMR signals of the N=CH group were absent. All these fact collect-
ively suggest the successful synthesis of all the above compounds. 
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The analytic and spectral data of all the synthesized compounds are given in 
the supplementary material to this paper. 
Biological testing 
The results of all the described activities (antibacterial, antifungal, antitu-
bercular and anti-inflammatory) are summarized in Tables I and II. The results of 
the antimicrobial screening data revealed that all the compounds 4a–m showed 
considerable and varied activity against the selected microorganisms. The results 
shown in Tables I and II revealed that all the synthesized compounds 4a–m have a 
structure activity relationship (SAR) because the activity of the compounds 
varied with substitution. The nitro group-containing compounds (4h, 4i and 4j) 
showed higher activity than the chloro (4c  and 4d), or bromo group containing 
compounds (4e and 4f). The chloro and bromo derivatives also had a higher activity 
than the other rested compounds. Based on the SAR, it can be concluded that the 
activity of the compounds depends on electron withdrawing nature of the substituent 
groups. The sequence of the activity is the following: NO2 > Cl > Br > OH > 
> OCH3 > CH3. 
TABLE I. Antibacterial, antifungal and antitubercular activities of compounds 4a–m. The 
MIC values of the standard streptomycin for all bacteria strains and griseofulvin for all fungi 
strains were in the range of 1.25–3.25 and 6.25–12.5 μg ml-1, respectively. Isoniazid and ri-
fampicin were used as standards, MIC values in the range of 1.25–2.50 μg ml-1, for M. 
tuberculosis 
Compd. 
Antibacterial activity  Antifungal activity  Antitubercular 
activity 
B. sub-
tilis 
E. 
coli 
S. au-
reus 
K. pneu-
moniae 
A. 
niger
A. 
flavus
F. oxi-
sporum 
C. al-
bicans
M. tuber- 
culosis 
4a  12.5 >6.25 12.5  6.25  >25  >25  >25  >25  >12.5 
4b  >3.25 6.25 3.25  >3.25  >25  >12.5 >25  >25  >2.50 
4c  6.25 >3.25 6.25  3.25  >12.5 25 >12.5  >12.5  >2.50 
4d  >3.25 6.25 3.25  6.25  >12.5 >25  >12.5  >12.5  2.50 
4e  6.25 >3.25 3.25  >3.25  >12.5 25  25  >25  >2.50 
4f  6.25 3.25 6.25  >3.25 >12.5 >12.5 >12.5 >12.5  >2.50 
4g  >3.25 6.25 >3.25  6.25  25  >12.5 >12.5  25  6.25 
4h  3.25 >3.25 3.25  3.25  25  >12.5 >12.5  >25  2.50 
4i  3.25 3.25  >3.25  3.25  >12.5 >12.5 >12.5 >12.5  2.50 
4j  3.25 >3.25 3.25  3.25  >12.5 >12.5 >12.5 >12.5  >2.50 
4k  >12.5 6.25 >12.5  6.25  25  25  >25  >25  12.5 
4l  >12.5 >12.5 >12.5  >12.5  >25  >25  >25  >25  >12.5 
4m  >3.25 >3.25  >6.25  >6.25 >25 25  >12.5 >12.5  6.25 
The investigation of antimicrobial (antibacterial, antifungal and antitubercular) 
data revealed that the compounds 4c, 4d, 4e, 4f, 4h, 4i and 4j displayed high activity, 
the compounds 4b, 4g and 4m showed moderate activity and the other compounds 
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showed low activity against all the strains compared with the standard drugs. In the 
anti-inflammatory activity test, compounds 4c, 4d, 4e, 4f, 4h, 4i and 4j showed high 
activity while the other compounds displayed moderate to low activity. 
TABLE II. Anti-inflammatory activity of compounds 4a–m 
Compound  Before carageenan administration
(mean±SEM) 
Total increase in paw volume 
after 5 h (mean±SEM)  Inhibition, % 
4a  0.62±0.02 0.18±0.02  48.57 
4b  0.65±0.02 0.16±0.02  54.29 
4c  0.66±0.02 0.16±0.01  54.29 
4d  0.64±0.02 0.17±0.02  51.43 
4e  0.66±0.03 0.15±0.02  57.14 
4f  0.67±0.02 0.14±0.01  60.00 
4g  0.66±0.02 0.16±0.01  54.29 
4h  0.65±0.03 0.14±0.01  60.00 
4i  0.68±0.02 0.13±0.03  62.86 
4j  0.67±0.03 0.12±0.02  65.71 
4k  0.65±0.02 0.16±0.02  54.29 
4l  0.64±0.02 0.18±0.02  48.57 
4m  0.67±0.02 0.16±0.01  54.29 
Control 0.68±0.02  0.35±0.01  – 
Standard; phe-
nylbutazone 
0.66±0.03 0.10±0.02  71.43 
CONCLUSIONS 
The research study reports the successful synthesis of compounds 1–4. The 
antimicrobial and antitubercular activity of the newly synthesized compounds 
bearing a 2-azetidinone moiety revealed that all the tested compounds showed 
moderate to good antibacterial, antifungal and antitubercular activities against the 
selected microbial strains. The results of the anti-inflammatory activity testing 
also showed positive results. Some of the compounds displayed promising ac-
tivities and are of interest for further transformations towards more potent deri-
vatives. 
SUPPLEMENTARY MATERIAL 
Аnalytical and spectral data of synthesized compounds are available elec-
tronically from http://www.shd.org.rs/JSCS/, or from the corresponding author 
on request. 
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ИЗВОД 
СИНТЕЗА И БИОЛОШКА АКТИВНОСТ 2-ОКСОАЗЕТИДИНСКИХ 
ДЕРИВАТА 2-АМИНОТИАЗОЛА  
PUSHKAL SAMADHIYA, RITU SHARMA, SANTOSH K. SRIVASTAVA и SAVITRI D. SRIVASTAVA 
Synthesis Organic Chemistry Laboratory, Department of Chemistry, Dr. H.S. Gour University, Sagar, 
Madhya Pradesh-470003, India 
Синтетисана је серија  нових деривата 3-хлоро-4-(супституисани фенил)-1-{[2-(тиазо-
лиламино)етил]амино}-2-азетидинона, једињења 4а–m, полазећи од 2-аминотиазола. Струк-
тура свих синтетисаних једињења потврђена је аналитичким и спектралним методамa, IC, 
1H-NMR и  13C-NMR спектроскопијом. Испитана је антибактеријска, антифунгална актив-
ност  према  одабраним  ћелијским  линијама  бактерија  и  гљива,  као  и  антитуберкулозна 
активност према  Mycobacterium tuberculosis синтетисаних једињења  4а–m. Антиинфлама-
торна  активност  је  испитана  према  албино  пацовима.  Резултати  показују  задовољавајућу 
активност тестираних једињења. 
(Примљено 5. јануара, ревидирано 16. јуна 2011) 
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